Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorKOUASSI, Arsene Kra
dc.contributor.authorSIMO FOTSO, Arlette
dc.contributor.authorROUVEAU, Nicolas
dc.contributor.authorMAHEU-GIROUX, Mathieu
dc.contributor.authorBOILY, Marie-Claude
dc.contributor.authorSILHOL, Romain
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorD'ELBEE, Marc
ORCID: 0000-0002-8827-019X
IDREF: 188117997
dc.contributor.authorVAUTIER, Anthony
dc.contributor.authorLARMARANGE, Joseph
dc.date.accessioned2024-09-05T08:47:51Z
dc.date.available2024-09-05T08:47:51Z
dc.date.issued2023-06-14
dc.date.conference2023-06-12
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201448
dc.description.abstractEnBackground HIV self-testing (HIVST) empowers individuals and allow them to decide when/where to test and with whom to share their result. Between 2019 and 2022, the ATLAS program distributed 400 000 HIVST kits in a mixed epidemic context (Côte d’Ivoire, Mali and Senegal), prioritizing key populations, including female sex workers (FSW) and men who have sex with men (MSM), and encouraged secondary distribution of HIVST to their partners, peers and FSW clients. To preserve its confidential nature, distributed HIVST kits were not systematically tracked. An anonymous phone survey was implemented among its users to estimate test positivity rates and linkage to confirmatory testing and care. Methods We conducted a two-step survey. Between March and June 2021, participants were recruited using dedicated leaflets distributed with HIVST kits, inviting users to call a free phone number anonymously (participation was rewarded USD $3.40) and to complete a sociobehavioural questionnaire (phase 1), including the self-reported number of visible lines on their HIVST kits and their interpretation of results. In September and October 2021, participants who reported a reactive HIVST result in phase 1 and agreed to be re-contacted were recalled to complete a short questionnaire (phase 2) on linkage to confirmatory testing and care. Results During phase 1, 2 615 participants were recruited: 2 346 (89.7%) reported a consistent HIVST result (2 visible lines and result interpreted as reactive; one line and interpreted as non-reactive; or no/one line and interpreted as invalid), 48 (1.8%) reported an inconsistent result and 221 (8.5%) did not know (DK) how to interpret their result or refused to answer. HIVST positivity rates ranged from 2.4% to 4.5%, depending on different assumptions (self-interpreted result or reported number of lines, inclusion or exclusion of DK and refusals). Among men who received an HIVST through activities targeting MSM, positivity rates ranged from 3.2% to 4.8%, and from 2.2% to 4.2% for women reached through activities targeting FSW. Among 126 phase 1 participants eligible for phase 2, 120 agreed to be re-contacted, and 78 fully completed the phase 2 questionnaire. Among the 27 who reported a consistent reactive result in the phase 1 questionnaire, 15 (56%, 95%CI: 36-74%) linked to confirmatory test, including 12 (80%) confirmed HIV-positive, which all started treatment (100%). Linkage was lower among those who reported an inconsistent result in phase 1(37%, 95%CI: 24-52%). Among those confirming reactive self-tests, 53% did it in less than one week following self-testing, and 91% in less than three months. Two-thirds (65%) went to a general public facility and one-third to a facility dedicated to key populations. Conclusion Our HIVST distribution strategy successfully reached people living with HIV in West Africa. Linkage to confirmatory testing remained sub-optimal in these first years of HIVST implementation. However, if confirmed HIV-positive, almost all initiated treatment. The majority of those who linked to confirmatory testing went to a general facility, suggesting that HIVST has the potential to reach more discrete populations. HIVST constitutes a complementary tool to existing screening services.
dc.language.isoENen_US
dc.title.enEstimating HIV self-testing positivity rate and linkage to confirmatory testing and care: a telephone survey in Côte d'Ivoire, Mali and Senegal
dc.typeCommunication dans un congrès
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titleAIDS Impact Conferenceen_US
bordeaux.countryseen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.conference.cityStockhlomen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
hal.proceedingsnonen_US
hal.conference.end2023-06-14
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2023-06-14&rft.au=KOUASSI,%20Arsene%20Kra&SIMO%20FOTSO,%20Arlette&ROUVEAU,%20Nicolas&MAHEU-GIROUX,%20Mathieu&BOILY,%20Marie-Claude&rft.genre=unknown


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record